Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta-analysis

IF 2.5 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Journal of Viral Hepatitis Pub Date : 2024-04-08 DOI:10.1111/jvh.13942

Fajuan Rui, Elizabeth Garcia, Xinyu Hu, Wenjing Ni, Qi Xue, Yayun Xu, Xiaoming Xu, Junping Shi, Mindie H. Nguyen, Ramsey C. Cheung, Jie Li

{"title":"Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta-analysis","authors":"Fajuan Rui, Elizabeth Garcia, Xinyu Hu, Wenjing Ni, Qi Xue, Yayun Xu, Xiaoming Xu, Junping Shi, Mindie H. Nguyen, Ramsey C. Cheung, Jie Li","doi":"10.1111/jvh.13942","DOIUrl":null,"url":null,"abstract":"The impact of concurrent fatty liver (FL) on response to antiviral therapy in chronic hepatitis B (CHB) patients has not been well characterized. We aimed to systematically review and analyse antiviral treatment response in CHB patients with and without FL. We searched PubMed, Embase, Web of Science and the Cochrane Library databases from inception to 31 May 2023 for relevant studies. Biochemical response (BR), complete viral suppression (CVS) and hepatitis B e antigen (HBeAg) seroconversion in CHB patients with FL (CHB-FL) and without FL (non-FL CHB) were compared. In an initial pool of 2101 citations, a total of 10 studies involving 2108 patients were included. After 12 weeks of treatment, CHB-FL patients as compared with non-FL CHB patients had lower BR rate (48.37% [108/227] vs. 72.98% [126/174], p = .04) but similar trend for CVS (36.86% [80/227] vs. 68.81% [114/174], p = .05) and similar rates of HBeAg seroconversion (6.59% [7/103] vs. 7.40% [7/110], p = .89). However, at week 48, there were no statistically significant differences between CHB-FL and non-FL CHB patients in any of the outcomes, including BR (60.03% [213/471] vs. 69.37% [314/717], p = .67), CVS (65.63% [459/746] vs. 73.81% [743/1132], p = .27) and HBeAg seroconversion (10.01% [30/275] vs. 14.06% [65/453], p = .58) with similar findings for week 96. BR rate was lower in CHB-FL patients after 12 weeks of antiviral treatment. However, after a longer follow-up of either 48 or 96 weeks, no statistically significant differences were observed in BR, CVS or HBeAg seroconversion rates between CHB patients with and without FL.","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Viral Hepatitis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvh.13942","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The impact of concurrent fatty liver (FL) on response to antiviral therapy in chronic hepatitis B (CHB) patients has not been well characterized. We aimed to systematically review and analyse antiviral treatment response in CHB patients with and without FL. We searched PubMed, Embase, Web of Science and the Cochrane Library databases from inception to 31 May 2023 for relevant studies. Biochemical response (BR), complete viral suppression (CVS) and hepatitis B e antigen (HBeAg) seroconversion in CHB patients with FL (CHB-FL) and without FL (non-FL CHB) were compared. In an initial pool of 2101 citations, a total of 10 studies involving 2108 patients were included. After 12 weeks of treatment, CHB-FL patients as compared with non-FL CHB patients had lower BR rate (48.37% [108/227] vs. 72.98% [126/174], p = .04) but similar trend for CVS (36.86% [80/227] vs. 68.81% [114/174], p = .05) and similar rates of HBeAg seroconversion (6.59% [7/103] vs. 7.40% [7/110], p = .89). However, at week 48, there were no statistically significant differences between CHB-FL and non-FL CHB patients in any of the outcomes, including BR (60.03% [213/471] vs. 69.37% [314/717], p = .67), CVS (65.63% [459/746] vs. 73.81% [743/1132], p = .27) and HBeAg seroconversion (10.01% [30/275] vs. 14.06% [65/453], p = .58) with similar findings for week 96. BR rate was lower in CHB-FL patients after 12 weeks of antiviral treatment. However, after a longer follow-up of either 48 or 96 weeks, no statistically significant differences were observed in BR, CVS or HBeAg seroconversion rates between CHB patients with and without FL.

查看原文本刊更多论文

慢性乙型肝炎和脂肪肝患者的抗病毒治疗反应：系统回顾和荟萃分析

慢性乙型肝炎（CHB）患者并发脂肪肝（FL）对抗病毒治疗反应的影响尚未得到很好的描述。我们的目的是系统回顾和分析有无脂肪肝的慢性乙型肝炎患者的抗病毒治疗反应。我们检索了 PubMed、Embase、Web of Science 和 Cochrane Library 数据库中从开始到 2023 年 5 月 31 日的相关研究。比较了FL型CHB（CHB-FL）和非FL型CHB（非FL型CHB）患者的生化应答（BR）、完全病毒抑制（CVS）和乙肝e抗原（HBeAg）血清转换情况。在最初的 2101 条文献中，共纳入了 10 项研究，涉及 2108 名患者。治疗 12 周后，与非 FL CHB 患者相比，CHB-FL 患者的 BR 率较低（48.37% [108/227] vs. 72.98% [126/174]，p = .04），但 CVS 的趋势相似（36.86% [80/227] vs. 68.81% [114/174]，p = .05），HBeAg 血清转换率相似（6.59% [7/103] vs. 7.40% [7/110]，p = .89）。然而，在第 48 周时，CHB-FL 和非FL CHB 患者在任何结果上都没有统计学意义上的显著差异，包括 BR（60.03% [213/471] vs. 69.37%[314/717]，P = .67）、CVS（65.63% [459/746] vs. 73.81% [743/1132]，P = .27）和 HBeAg 血清转换（10.01% [30/275] vs. 14.06% [65/453]，P = .58），第 96 周的结果类似。抗病毒治疗 12 周后，CHB-FL 患者的 BR 率较低。然而，在经过 48 周或 96 周的长期随访后，在有 FL 和无 FL 的 CHB 患者之间，BR、CVS 或 HBeAg 血清转换率没有观察到显著的统计学差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Viral Hepatitis 医学-病毒学

CiteScore

6.00

自引率

8.00%

发文量

138

审稿时长

1.5 months

期刊介绍： The Journal of Viral Hepatitis publishes reviews, original work (full papers) and short, rapid communications in the area of viral hepatitis. It solicits these articles from epidemiologists, clinicians, pathologists, virologists and specialists in transfusion medicine working in the field, thereby bringing together in a single journal the important issues in this expanding speciality. The Journal of Viral Hepatitis is a monthly journal, publishing reviews, original work (full papers) and short rapid communications in the area of viral hepatitis. It brings together in a single journal important issues in this rapidly expanding speciality including articles from: virologists; epidemiologists; clinicians; pathologists; specialists in transfusion medicine.